NO_LONGER_AVAILABLENot Applicable

Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19

United States

Plain-language summary

Prospective, observational, clinical investigation of PMX cartridge use in COVID 19 patients with septic shock

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Age ≥ 18 years of age
✓. Hypotension requiring vasopressor support: Requirement for at least one of the vasopressors listed below, at the dose shown below, for at least 2 continuous hours and no more than 30 hours
✓. Norepinephrine \> 0.05mcg/kg/min
✓. Dopamine \> 10 mcg/kg/min
✓. Phenylephrine \> 0.4 mcg/kg/min
✓. Epinephrine \> 0.05 mcg/kg/min
✓. Vasopressin \> 0.03 units/min
✓. Vasopressin (any dose) in combination with another vasopressor listed above

✕. Inability to obtain an informed consent from the subject, family member or an authorized surrogate
✕. Lack of commitment for full medical support
✕. Inability to achieve or maintain a minimum mean arterial pressure (MAP) of ≥ 65mmHg despite vasopressor therapy and fluid resuscitation
✕. Subject has end-stage renal disease and requires chronic dialysis
✕. There is clinical support for non-septic shock such as:
✕. Acute pulmonary embolus
✕. Transfusion reaction
✕. Severe congestive heart failure (e.g. NYHA Class IV, ejection fraction \< 35%)

NCT IDNCT04352985

SponsorSpectral Diagnostics (US) Inc.

Sponsor typeINDUSTRY

Study typeEXPANDED_ACCESS